GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: In addition to improve glucose intolerance, recent studies suggest that glucagon-like peptide-1 (GLP-1) receptor agonism also decreases triglyceride (TG) levels. The aim of this study was to evaluate the effect of GLP-1 receptor agonism on very-low-density lipoprotein (VLDL)-TG production and liver TG metabolism. EXPERIMENTAL APPROACH: The GLP-1 peptide analogues CNTO3649 and exendin-4 were continuously administered subcutaneously to high fat diet-fed APOE*3-Leiden transgenic mice. After 4 weeks, hepatic VLDL production, lipid content, and expression profiles of selected genes involved in lipid metabolism were determined. RESULTS: CNTO3649 and exendin-4 reduced fasting plasma glucose (up to -30% and -28% respectively) and insulin (-43% and -65% respectively). In addition, these agents reduced VLDL-TG production (-36% and -54% respectively) and VLDL-apoB production (-36% and -43% respectively), indicating reduced production of VLDL particles rather than reduced lipidation of apoB. Moreover, they markedly decreased hepatic content of TG (-39% and -55% respectively), cholesterol (-30% and -55% respectively), and phospholipids (-23% and -36% respectively), accompanied by down-regulation of expression of genes involved in hepatic lipogenesis (Srebp-1c, Fasn, Dgat1) and apoB synthesis (Apob). CONCLUSION: GLP-1 receptor agonism reduces VLDL production and hepatic steatosis in addition to an improvement of glycemic control. These data suggest that GLP-receptor agonists could reduce hepatic steatosis and ameliorate dyslipidemia in patients with type 2 diabetes mellitus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Subsequent research conducted by Parlevliet et al. 55 substantiates this point while also revealing both DPP-1i (exendin-4) and GLP1-RA result in decreased hepatic lipogenesis among mice consuming high-fat diets.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [55]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They also discovered that treatment with GLP-1 suppresses the activity of genes participating in lipogenesis.”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [55]
In the citing paper
“It has been proposed that GLP-1RA ameliorate hepatic steatosis by increasing fatty acid oxidation, enhancing very-low-density lipoprotein (VLDL) secretion and inhibiting lipogenesis [170,180].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [180]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751 · cited 2×
“Hepatic lipid content Liver lipids were extracted according to a modified protocol from Bligh and Dyer [21].”
MethodMechanisms linking obesity to insulin resistance and type 2 diabetes
Kahn, S. E., Hull, R. L., & Utzschneider, K. M. (2006) · Nature · doi:10.1038/nature05482 · Cited by 5,448 · cited 1×
“Type 2 diabetes mellitus (T2DM) has become a major metabolic disorder in both developed and developing countries, with impaired glucose tolerance and insulin resistance as hallmarks [1,2].”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“However, therapeutic application of GLP-1 is hampered due to its short circulating halflife (,2 minutes), because it is rapidly degraded by dipeptidyl peptidase 4 (DPP-4) that is widely expressed in endothelium and intestinal mucosa [10].”
BackgroundDonnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 1×
“Since uptake of TG from the diet eventually contributes to VLDL-TG production [37,38], reduced chylomicron production may contribute to the observed effect of GLP-1 receptor agonism on hepatic VLDL production.”
BackgroundType 2 diabetes: principles of pathogenesis and therapy
Stumvoll, M., Goldstein, B. J., & van Haeften, T. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)61032-x · Cited by 2,662 · cited 1×
“Type 2 diabetes mellitus (T2DM) has become a major metabolic disorder in both developed and developing countries, with impaired glucose tolerance and insulin resistance as hallmarks [1,2].”
BackgroundA role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950 · cited 1×
“Additionally, GLP-1 exerts multiple other effects, including inhibition of food intake [7], slowing gastric emptying [8], and inhibition of glucagon secretion [9].”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 2×
“GLP-1 is an incretin hormone produced by intestinal L cells and the brain [4,5].”
BackgroundZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“with earlier reports that GLP-1 and its analogs ameliorate wholebody glucose intolerance in obese animal models [23,24] and in T2DM patients [25].”
BackgroundSeparation of plasma lipoproteins by density-gradient ultracentrifugation
Redgrave, T. G., Roberts, D. C. K., & West, C. E. (1975) · Analytical Biochemistry · doi:10.1016/0003-2697(75)90488-1 · Cited by 1,107 · cited 1×
“At 120 min, mice were euthanized, and blood was collected by orbital puncture for isolation of VLDL by density gradient ultracentrifugation [19].”
MethodKlonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 13×
“It is known that the contribution of de novo lipogenesis to total hepatic VLDL secretion strongly increases from 2–5% under healthy conditions up to 25– 30% in T2DM patients with hepatic steatosis [28,29].”
BackgroundInfluential
Cited by
Dysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 554
“In high-fat dietfed ApoE*3-Leiden CETP-transgenic mice, GLP1-R agonist treatment decreased hepatic steatosis and plasma TG by respectively decreasing DNL and VLDL production [187].”
BackgroundAnti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications
Alharbi, S. H. (2024) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231222367 · Cited by 358
Cardiovascular Actions of Incretin-Based Therapies
Ussher, J. R., & Drucker, D. J. (2014) · Circulation Research · doi:10.1161/circresaha.114.301958 · Cited by 358
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
Arguello, G., Balboa, E., Arrese, M., & Zanlungo, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.015 · Cited by 306
Lipid Processing in the Brain: A Key Regulator of Systemic Metabolism
Bruce, K. D., Zsombok, A., & Eckel, R. H. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00060 · Cited by 262
Fatty Acids Consumption: The Role Metabolic Aspects Involved in Obesity and Its Associated Disorders
Silva Figueiredo, P., Carla Inada, A., Marcelino, G., Maiara Lopes Cardozo, C., De Cássia Freitas, K., De Cássia Avellaneda Guimarães, R., Pereira de Castro, A., Aragão do Nascimento, V., & Aiko Hiane, P. (2017) · Nutrients · doi:10.3390/nu9101158 · Cited by 239
“The data showed that a diet rich in SFA exerted a hyperlipidemic effect only on the 30th day, but a long-term diet displayed beneficial effects on hyperlipidemia (Table 4) [73], which could be a consequence of the decrease in apolipoprotein synthesis and the formation of VLDL in the liver [74,75].”
BackgroundGlucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 175
“Administration of the GLP-1RA CNTO3649 or exendin-4 for 4 weeks reduced hepatic TG and cholesterol and decreased levels of VLDL-TG and VLDL-apoB production in HFD-fed ApoE*3 Leiden transgenic mice (23).”
Kooijman, S., Wang, Y., Parlevliet, E. T., Boon, M. R., Edelschaap, D., Snaterse, G., Pijl, H., Romijn, J. A., & Rensen, P. C. N. (2015) · Diabetologia · doi:10.1007/s00125-015-3727-0 · Cited by 140
“chronic peripheral exendin-4 treatment [27].”
Self-citationGeerling, J. J., Boon, M. R., Kooijman, S., Parlevliet, E. T., Havekes, L. M., Romijn, J. A., Meurs, I. M., & Rensen, P. C. N. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r045013 · Cited by 137
“Based on this review, GLP-1 receptor agonists might be a promising new therapeutic strategy, as GLP-1 receptor activation decreases hepatic lipogenesis (37, 38) and VLDL-TG production (8), increases lipolysis (38) and decreases lipogenesis in WAT (50), and increases thermogenesis by BAT (77).”
BackgroundSelf-citationWang, Y., Parlevliet, E. T., Geerling, J. J., van der Tuin, S. J. L., Zhang, H., Bieghs, V, Jawad, A. H. M., Shiri‐Sverdlov, R., Bot, I., de Jager, S. C. A., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12490 · Cited by 126
“Based on our collective findings that exendin-4 reduces high-fat diet-induced hepatic steatosis by decreasing lipogenesis (Parlevliet et al., 2012) and suppresses macrophage content in both vessel wall and liver (in the current study), we propose that exendin-4 is a suitable candidate to concomitantly treat atheroscle…”
BackgroundResultSelf-citationBizino, M. B., Jazet, I. M., de Heer, P., van Eyk, H. J., Dekkers, I. A., Rensen, P. C. N., Paiman, E. H. M., Lamb, H. J., & Smit, J. W. (2020) · Diabetologia · doi:10.1007/s00125-019-05021-6 · Cited by 123
Self-citationNonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
Fruci, B., Giuliano, S., Mazza, A., Malaguarnera, R., & Belfiore, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122933 · Cited by 107
Monji, A., Mitsui, T., Bando, Y. K., Aoyama, M., Shigeta, T., & Murohara, T. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00990.2012 · Cited by 104
“demonstrated that GLP-1 agonism markedly decreased hepatic content of cholesterols and 333 phospholipids, accompanied by down-regulation of hepatic lipogenesis-related genes and apoB 334 synthesis (26).”
BackgroundMolecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity
Yaribeygi, H., Sathyapalan, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116776 · Cited by 102
GLP-1/GLP-1R signaling in regulation of adipocyte differentiation and lipogenesis
Chen, J., Zhao, H., Ma, X., Zhang, Y., Lu, S., Wang, Y., Zong, C., Qin, D., Wang, Y., Yingfeng Yang, Y., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000478872 · Cited by 94
Self-citationTaher, J., Baker, C. L., Cuizon, C., Masoudpour, H., Zhang, R., Farr, S., Naples, M., Bourdon, C., Pausova, Z., & Adeli, K. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.09.005 · Cited by 90
Decara, J., Rivera, P., Arrabal, S., Vargas, A., Serrano, A., Pavón, F. J., Dieguez, C., Nogueiras, R., Rodríguez de Fonseca, F., & Suárez, J. (2018) · Acta Physiologica · doi:10.1111/apha.13008 · Cited by 76
“GLP-1 receptor agonists (exendin-4, 15-50 lg kg 1 d (1)) have been proposed for the treatment of dyslipidaemia (defined as LDL-cholesterol and triglyceride elevation and highdensity lipoprotein (HDL) lowering in plasma) in T2D patients.(26) GLP1 receptor activation could reduce VLDL overproduction, plasma levels of tr…”
BackgroundAroor, A. R., Habibi, J., Ford, D. A., Nistala, R., Lastra, G., Manrique, C., Dunham, M. M., Ford, K. D., Thyfault, J. P., Parks, E. J., et al. (2015) · Diabetes · doi:10.2337/db14-0804 · Cited by 76
“Interestingly, GLP-1 receptor activation with exendin-4 reversed hepatic steatosis (32,33), in part by decreasing hepatic lipogenesis but not through enhancing hepatic VLDL production (33) as we have shown with DPP-4 inhibition in the current study.”
BackgroundMoon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 86
GLP-1 receptor agonists in NAFLD
Petit, J.-M., & Vergès, B. L. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30070-8 · Cited by 77
The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution
Zhao, L., Zhu, C., Lu, M., Chen, C., Nie, X., Abudukerimu, B., Zhang, K., Ning, Z., Chen, Y., Cheng, J., et al. (2019) · Journal of Endocrinology · doi:10.1530/joe-18-0374 · Cited by 67
Bifari, F., Manfrini, R., Dei Cas, M., Berra, C., Siano, M., Zuin, M., Paroni, R., & Folli, F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 69
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
GLP-1 based therapies: clinical implications for gastroenterologists
Smits, M. M., van Raalte, D. H., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., & Cahen, D. L. (2016) · Gut · doi:10.1136/gutjnl-2015-310572 · Cited by 61
“144 145 In addition, GLP-1 in fl uences bile metabolism.”
BackgroundQassab, M. A., Mneimneh, M., Jradi, A., Derbas, B., Dabboussi, D., Baini, J. K., Katrib, N., Chaarani, N., Attieh, P., Kanaan, A., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040285 · Cited by 64
“They also decreased hepatic very-low-density lipoprotein (VLDL) production by reducing the expression of SREBP-1c and fatty acid synthase (FASN) [34,46].”
Yang, S.-H., Xu, R.-X., Cui, C.-J., Wang, Y., Du, Y., Chen, Z.-G., Yao, Y.-H., Ma, C.-Y., Zhu, C.-G., Guo, Y.-L., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0689-9 · Cited by 56
“production [39]; (3) to slow gastric emptying and to reduce lipase activity [40]; (4) to decrease VLDL production, lipogenesis and ApoB100 production [41, 42]; (5) to inhibit fat oxidation and to promote thermogenesis [43]; (6) the effect of decreased PCSK9 by liraglutide on cholesteryl ester transfer protein (CETP) i…”
BackgroundSelf-citationJanssen, L. G. M., Nahon, K. J., Bracké, K. F. M., van den Broek, D., Smit, R., Sardjoe Mishre, A. S. D., Koorneef, L. L., Martinez-Tellez, B., Burakiewicz, J., Kan, H. E., et al. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154167 · Cited by 54
Self-citationVergès, B., Duvillard, L., Pais de Barros, J. P., Bouillet, B., Baillot-Rudoni, S., Rouland, A., Petit, J. M., Degrace, P., & Demizieux, L. (2021) · Diabetes Care · doi:10.2337/dc20-1843 · Cited by 54
Lee, H. A., & Kim, H. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119324 · Cited by 48
“The potential benefits of GLP-1RAs in lipid metabolism have been demonstrated in experimental studies; GLP-1RAs reduced very-low-density lipoprotein (VLDL) production and the hepatic expression of genes involved in VLDL production and lipogenesis, such as SREBP-1c and fatty acid synthase [33].”
BackgroundPiccirillo, F., Mastroberardino, S., Nusca, A., Frau, L., Guarino, L., Napoli, N., Ussia, G. P., & Grigioni, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210164 · Cited by 58
“Furthermore, in high-fat-fed mice, the administration of GLP-1 RAs reduced VLDL cholesterol production and hepatic steatosis, other than better glycemic control [75].”
BackgroundGLP‐1 receptor agonists: effects on the progression of non‐alcoholic fatty liver disease
Liu, J., Wang, G., Jia, Y., & Xu, Y. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2580 · Cited by 48
“In high fat diet-fed APOE*3-Leiden transgenic mice, GLP-1 receptor agonist treatment for 4 weeks significantly decreases hepatic lipid content and reverses high-fat-diet-induced hepatic steatosis [33].”
BackgroundInfluentialEffect of the prolonged high-fat diet on the fatty acid metabolism in rat blood and liver
Zhukova, N. V., Novgorodtseva, T. P., & Denisenko, Y. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-49 · Cited by 51
“Ration rich in saturated fats may inhibit the VLDL synthesis in the liver [21,22].”
BackgroundNonalcoholic Steatohepatitis Drug Development Pipeline: An Update
Chew, N., Ng, C. H., Truong, E., Noureddin, M., & Kowdley, K. V. (2022) · Seminars in Liver Disease · doi:10.1055/a-1877-9656 · Cited by 52
Khalifa, O., AL-Akl, N. S., Errafii, K., & Arredouani, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-06143-5 · Cited by 42
Decara, J., Arrabal, S., Beiroa, D., Rivera, P., Vargas, A., Serrano, A., Pavón, F. J., Ballesteros, J., Dieguez, C., Nogueiras, R., et al. (2016) · BioFactors · doi:10.1002/biof.1295 · Cited by 42
Liu, C., Hu, M., Zhang, M., Li, F., Li, J., Zhang, J., Li, Y., Guo, H., Xu, P., Liu, L., et al. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.015 · Cited by 40
“Recent studies have demonstrated that GLP-1 and GLP-1 analogs have the potential to improve hyperlipidemia and insulin resistance [6–10].”
BackgroundLiu, Y., Huang, Z., Wang, L., Liu, X., Wang, Y.-M., Zhang, Y., & Zhang, M. (2014) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2014.12.007 · Cited by 38
Self-citationGlucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: An update
Sofogianni, A., Filippidis, A., Chrysavgis, L., Tziomalos, K., & Cholongitas, E. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i8.493 · Cited by 33
Tate, M., Chong, A., Robinson, E., Green, B. D., & Grieve, D. J. (2015) · British Journal of Pharmacology · doi:10.1111/bph.12943 · Cited by 33
“…develop severe hypercholesterolaemia after high-fat feeding, resulted in reduced very-low-density lipoprotein (VLDL)-triglyceride and apolipoprotein B synthesis in parallel with decreased hepatic triglyceride, cholesterol and phospholipids and lipogenesis gene expression (Parlevliet et al., 2012).”
BackgroundInfluentialHasegawa, Y., Hori, M., Nakagami, T., Harada‐Shiba, M., & Uchigata, Y. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.11.006 · Cited by 33
Oligonucleotide therapies for nonalcoholic steatohepatitis
Li, S., Xiong, F., Zhang, S., Liu, J., Gao, G., Xie, J. H., & Wang, Y. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102184 · Cited by 35
Self-citationFrom Liver Fat to Cancer: Perils of the Western Diet
Kim, J. Y., He, F., & Karin, M. (2021) · Cancers · doi:10.3390/cancers13051095 · Cited by 33
“Cancers 2021, 13, 1095 12 of 19 Other potential approaches to reduce liver Chol or to decrease Chol-mediated liver injury for the treatment of NASH and HCC include thyroid hormone receptor agonists [151], activation of the glucagon-like peptide-1 receptor (GLP-1R) [152], and genetic deletion or silencing of miR-122 [1…”
BackgroundGLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis
Chen, Y., Xu, Y.-N., Ye, C.-Y., Feng, W., Zhou, Q., Yang, D., & Wang, M. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00836-9 · Cited by 34
“In addition, exendin-4 was shown to decrease apoB-100 synthesis leading to decreased VLDL production [66].”
BackgroundPostprandial dysmetabolism: Too early or too late?
Pappas, C., Kandaraki, E., Tsirona, S., Kountouras, D., Kassi, G., & Diamanti‐Kandarakis, E. (2016) · HORMONES · doi:10.14310/horm.2002.1697 · Cited by 33
Li, J., Guan, M., Li, C., Lyv, F., Zeng, Y., Zheng, Z., Wang, C., & Xue, Y. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150711416 · Cited by 30
The Impact of Incretin-Based Medications on Lipid Metabolism
Yaribeygi, H., Maleki, M., Butler, A. E., Jamialahmadi, T., & Sahebkar, A. (2021) · Journal of Diabetes Research · doi:10.1155/2021/1815178 · Cited by 33
“in 2012 provided further evidence demonstrating that both GLP-1RA (CNTO3649) and DPP-4i (exendin-4) decrease hepatic lipogenesis in HFD mice [59].”
BackgroundBariatric surgery and nonalcoholic fatty liver disease
Bower, G., Athanasiou, T., Martínez-Isla, A., Harling, L., Li, J. V., Holmes, E. C., Efthimiou, E., Darzi, A. W., & Ashrafian, H. (2015) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000375 · Cited by 30
Taher, J., Baker, C., ALVARES, D. C. L., Ijaz, L., Hussain, M. M., & Adeli, K. (2018) · Endocrinology · doi:10.1210/en.2018-00416 · Cited by 29
Complex role of autophagy in regulation of hepatic lipid and lipoprotein metabolism
Mostafa, Z., Taher, J., & Adeli, K. (2016) · Journal of Biomedical Research · doi:10.7555/jbr.30.20150137 · Cited by 31
Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice
Ying, Z., van Eenige, R., Ge, X., van Marwijk, C., Lambooij, J. M., Guigas, B., Giera, M. A., de Boer, J. F., Coşkun, T., Qu, H., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104684 · Cited by 28
Self-citationOkubo, H., Nakatsu, Y., Sakoda, H., Kushiyama, A., Fujishiro, M., Fukushima, T., Matsunaga, Y., Ohno, H., Yoneda, M., Kamata, H., et al. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00198.2014 · Cited by 23
Liraglutide improves lipid and carbohydrate metabolism of ovariectomized rats
Model, J. F. A., Lima, M. V., Ohlweiler, R., Vogt, É. L., Rocha, D. S., de Souza, S. K., Türck, P., Araújo, A. S. D. R., & Vinagre, A. S. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111158 · Cited by 24
Gitto, M., Catapano, F., Francone, M., Mincione, G., Scialò, V., Pivato, C. A., Lisi, C., Regazzoli, D., Cao, D., Fiorina, R. M., et al. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02606-z · Cited by 25
“The observed reduction in MAG and TAG aligns with the known effects of GLP-1Ra in decreasing fat accumulation and enhancing lipolysis, contributing to weight loss [ 32, 33 ].”
ALVARES, D. C. L., HOFFMAN, S. S., Stankovic, B., & Adeli, K. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2018.12.010 · Cited by 22
Gao, Z., Song, G., Ren, L., Ma, H., Ma, B., & Chen, S. (2020) · European Journal of Histochemistry · doi:10.4081/ejh.2020.3160 · Cited by 23
Dhanesha, N., Joharapurkar, A. A., Shah, G. B., Kshirsagar, S. G., PATEL, V. G., Patel, K., Bahekar, R. H., & Jain, M. R. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.06.015 · Cited by 21
van Eenige, R., Ying, Z., Tramper, N., Wiebing, V., Siraj, Z., de Boer, J. F., Lambooij, J. M., Guigas, B., Qu, H., Coşkun, T., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.016 · Cited by 20
Self-citationPreventing Oxidative Stress in the Liver: An Opportunity for GLP-1 and/or PASK
Hurtado-Carneiro, V., Dongil, P., Pérez-García, A., Álvarez, E., & Sanz, C. (2021) · Antioxidants · doi:10.3390/antiox10122028 · Cited by 20
Li, B., Luo, Y., Tian, F., Chen, Y., Tian, J., Ding, Y., Mei, Z., Li, J., Zhang, Y.-Q., & Shi, W. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.03.015 · Cited by 17
Rivera, F. B., Chin, M. N. C., Pine, P. L. S., Ruyeras, M. M. J., Galang, D. J. C., Gandionco, K. M., Morales, B. L. F. D., Climaco, Z. M. V., Bantayan, N. R. B., Magalong, J. V., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2442027 · Cited by 20
“GLP-1 RAs may enhance the clearance of triglyceride-rich lipoproteins, reduce hepatic secretion of VLDL particles, and influence gene expression related to lipid metabolism 57–59 .”
Exenatide reverses dysregulated microRNAs in high-fat diet-induced obese mice
Lee, I. S., Park, K. C., Yang, K., Choi, H., Jang, Y. S., Lee, J. M., & Kim, H. S. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.07.011 · Cited by 16
Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors
Zhong, J., Maiseyeu, A., & Rajagopalan, S. (2015) · Clinical Lipidology · doi:10.2217/clp.14.59 · Cited by 16
Exendin-4 protects mice from D-galactose-induced hepatic and pancreatic dysfunction
Ahangarpour, A., Oroojan, A. A., & Badavi, M. (2017) · Pathobiology of Aging & Age-related Diseases · doi:10.1080/20010001.2017.1418593 · Cited by 15
“[18] indicated that this drug could reduce hepatic steatosis and ameliorate dyslipidemia by decreasing serum levels of VLDL and TG.”
BackgroundIntestinal L-cell mechanoreception regulates hepatic lipid metabolism through GLP-1
Gao, L., Yang, K., Zhao, Y., Zhang, J., Jiang, S., Zhang, R., He, W., Zhao, Y., Ye, Q., & Xu, G. (2025) · Science Advances · doi:10.1126/sciadv.adv3201 · Cited by 14
“It can be involved in lipid metabolism by inhibiting fat synthesis ( 35 ), promoting fat differentiation ( 10 ), enhancing cholesterol metabolism ( 36 ), and promoting fat browning ( 37 ).”
Ni, Z., Zhang, Y., Wang, H., Wei, Y., Ma, B., Hao, J., Tu, P., Duan, H., Li, X., Jiang, P., et al. (2016) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-016-1979-x · Cited by 12
Incretins and MASLD: at the Crossroads of Endocrine and Hepatic Disorders
Farrugia, M. A., Pini, E., Tran, A., Chevalier, N., Anty, R., & Gual, P. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00646-8 · Cited by 12
“In HFD-fed mice, GLP-1RA treatment reduced the hepatic cholesterol and triglyceride content, and liver lipogenesis as measured by the expression of Fasn and Dgat1 [70, 71].”
PATEL, V. G., Joharapurkar, A. A., Kshirsagar, S. G., Patel, H., Pandey, D., Patel, D. N., Sutariya, B., Patel, M. S., Bahekar, R. H., & Jain, M. R. (2017) · Drug Research · doi:10.1055/s-0043-118808 · Cited by 11
“Drug Res 2017; 67: 730–736 It is interesting to note that GLP-1 agonists reduce postprandial dyslipidemia, triglycerides, LDL and total cholesterol [8, 9].”
BackgroundYildirim, V., ter Horst, K. W., Gilijamse, P. W., van Harskamp, D., Schierbeek, H., Jansen, H., Schimmel, A. W. M., Nieuwdorp, M., Groen, A. K., Serlie, M. J. M., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.166905 · Cited by 10
“GLP-1 reduces intestinal chylomicron production and secretion (69, 70) and activation of GLP-1 receptors reduces hepatic VLDL production (71, 72).”
Exendin-4 as a Versatile Therapeutic Agent for the Amelioration of Diabetic Changes
Rajabi, H., Ahmadi, M., Aslani, S., Saberianpour, S., & Rahbarghazi, R. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.025 · Cited by 11
“Fasn participates in de novo lipogenesis and Dgat1 promotes the last steps in hepatic three glyceride synthesis.(102) It was found that Sirt-1 expression is decreased in high-fat-diet animal models and Ex4 could reverse the Sirt-1 function either in in vivo and in vitro models coincided with”
BackgroundSahraoui, A., Winzell, M. S., Gorman, T., Smith, D. M., Skrtic, S., Høyem, M., Abadpour, S., Johansson, L., Korsgren, O., Foss, A. E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121204 · Cited by 9
“Parlevliet et al [30] showed that exendin-4 reduces hepatic lipogenesis, which caused a reduction in hepatic triglyceride content, hence the reduction of circulating triglycerides.”
BackgroundBrain Control of Plasma Cholesterol Involves Polysialic Acid Molecules in the Hypothalamus
Brénachot, X., Gautier, T., Nédélec, E., Deckert, V., Laderrière, A., Nuzzaci, D., Rigault, C., Lemoine, A., Pénicaud, L., Lagrost, L., et al. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00245 · Cited by 10
“More recently, it has been shown that circulating hormones such as leptin (Vanpatten et al., 2004), insulin (Scherer et al., 2016), and Glp-1 (Parlevliet et al., 2012; Panjwani et al., 2013; Taher et al., 2014), trigger brain-mediated regulation of hepatic cholesterol metabolism.”
Bernardini, F., Nusca, A., Coletti, F., Porta, Y. L., Piscione, M., Vespasiano, F., Mangiacapra, F., Ricottini, E., Melfi, R., Cavallari, I., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071858 · Cited by 9
“demonstrated that GLP-1RA and DPP-4i inhibited hepatic lipogenesis in high-fat diet mice through AMPK regulation [133].”
BackgroundZhang, M., Jiang, W., Yin, J. L., & Xiao, D. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.036 · Cited by 11
“In a study with mice fed a HFD, activating the GLP-1 receptor led to decreased VLDL particle production and downregulated hep-atic lipogenesis-related gene expression ( Srebp-1c , Fasn , Dgat1 ) [110].”
Acute Cholesterol-Lowering Effect of Exendin-4 in Ldlr−/− and C57BL/6J Mice
Hori, M., Hasegawa, Y., Hayashi, Y., Nakagami, T., & Harada‐Shiba, M. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60921 · Cited by 8
Li, C., Zhao, L., Zhou, X., Wu, H., & Zhao, J. (2015) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-015-1433-2 · Cited by 8
Li, C., Hou, S., Liu, S., Huan, Y., Sun, S., Liu, Q., & Shen, Z. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0143-8 · Cited by 7
“CNTO3649, a GLP-1 analog, after being continuously administered subcutaneously to APOE*3-leiden transgenic mice, fed on a high fat die, markedly reduced very low-density lipoprotein production and hepatic steatosis, in addition to improving glycemic control [24].”
Drexel, H., Festa, A., Schmidt, T. A., Rocca, B., Dobrev, D., Agewall, S., Tamargo, J. L., & Kaser, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf076 · Cited by 7
“134,135”
GLP-1/GLP-1RAs: New Options for the Drug Treatment of NAFLD
Jiang, H., & Zang, L. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128283153231226103218 · Cited by 7
Cheng, Y., Gong, S., Li, Q., Shen, J., & Huang, H. (2024) · Journal of Cancer · doi:10.7150/jca.97637 · Cited by 5
“Total cholesterol (TC) is a major component of cell membranes and is crucial for normal cellular structure and function [34].”
BackgroundBaragetti, A. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.09 · Cited by 6
Lee, J., Rhee, E., Lim, Y.-M., Hong, S., & Lee, W. (2025) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2025.7.e11 · Cited by 3
Ji, W.-W., Yu, D., Fan, M., You, M., Lü, Y., Li, E.-B., Xie, N., & Yan, S. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-0992-z · Cited by 3
“Recent studies showed that GLP-1R agonists could reduce the TG level [25, 26].”
BackgroundOshaghi, E. A. (2017) · Avicenna Journal of Medical Biochemistry · doi:10.15171/ajmb.2017.10 · Cited by 3
Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease
Koo, B. K., & Lim, S. K. (2022) · Wiley eBooks · doi:10.1002/9781119695257.ch13 · Cited by 3
Soyaltın, U. E., Şimşir, İ. Y., & Akıncı, B. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02633-w · Cited by 2
Bile acids and incretins as modulators of obesity-associated atherosclerosis
Kirsch, A., Gindlhuber, J., Zabini, D., & Osto, E. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1510148 · Cited by 3
One feature doesn't fit all: characterizing topological features of targets in signaling networks
Chua, H. E., Bhowmick, S. S., & Tucker‐Kellogg, L. (2014) · ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB) · doi:10.1145/2649387.2649424 · Cited by 3
“CNTO 3649 [344] 00882726 activated GLP-1 receptor GLP-1 peptide analogue.”
BackgroundAutophagy in MASLD : A Metabolic and Precision Medicine Perspective
Cazzaniga, A., Frigo, S., Cherubini, A., Rrapaj, E., & Valenti, L. V. C. (2026) · Liver International · doi:10.1111/liv.70816 · Cited by 1
Niyomugabo, A. P., Ntakirutimana, L., Izabayo, P., Isingizwe, C., Onaadepo, O., & Alagbonsi, A. I. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261492402 · Cited by 3
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
陈, 舒. (2025) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2025.43402
Chen, J., Liu, K.-W., Huang, Y., Meyerowitz‐Katz, G., Tsai, T., & Su, P. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261460592 · Cited by 1
“26”
Glucagon-like peptide-1 regulates lipid metabolism through actions in the gut and liver
Lewis, G. F., Feng, J. N., & Jin, T. (2026) · Metabolism and Diseases · doi:10.1016/j.metdis.2026.100023
Liraglutide reduces lipid accumulation in human orbital fibroblasts in Graves’ orbitopathy
Shih, C.-W., Shih, S.-R., Wei, Y.-H., LIN, C.-H., Shu-Lang, L., Chou, T.-A., Chu, I., Chen, H.-J., Liao, N.-L., & Tsai, F. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1914378
“In 3T3-L1 adipocytes, liraglutide suppresses fatty acid synthase, a key enzyme involved in de novo lipogenesis (16). studies further demonstrate that GLP-1 and its analogs reduce hepatic lipid content and downregulate lipogenic gene expression in high-fat – fed mice (17).”
Mikhael, F. G., Ayoub, C., Teperikidis, E., Biondi-Zoccai, G., Booz, G. W., Zouein, F. A., & Makarem, N. N. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01471-7
“Mechanistically, GLP-1R activation has been demonstrated in experimental models to downregulate hepatic lipogenic pathways and VLDL production [29].”
Metadata
- Authors
- Parlevliet, E. T., Wang, Y., Geerling, J. J., Schröder-Van der Elst, J. P., Picha, K., O'Neil, K., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., Pijl, H., & Rensen, P. C. N.
- Affiliations
- Leiden University Medical Center (NL)
- Janssen Research & Development (United States) (US)
- Netherlands Organisation for Applied Scientific Research (NL)
- Corresponding author
- Rensen, Patrick C. N.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-11-02
- Volume
- 7
- Issue
- 11
- Pages
- e49152
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3487842
- OpenAlex
- W2139855450
- Cited by
- 97
- References
- 45
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 5 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 6 · 2019: 2 · 2018: 5 · 2017: 13 · 2016: 5 · 2015: 8 · 2014: 11 · 2013: 5
- FWCI
- 4.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- TNO Repository (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- GLP-1 receptor agonism, glucagon-like peptide-1, VLDL production, hepatic steatosis, hepatic lipogenesis, exendin-4, APOE*3-Leiden mice, high-fat diet, dyslipidemia, type 2 diabetes, hepatic triglyceride metabolism, apolipoprotein B, SREBP-1c, fatty acid synthase, insulin, glycemic control
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Apolipoproteins B, Blood Glucose, Diabetes Mellitus, Type 2, Fatty Liver, Insulin, Liver, Male, Mice, Transgenic, Peptides, Venoms, Receptors, Glucagon, Lipogenesis, Dyslipidemias, Mice, Glucagon-Like Peptide 1, Apolipoprotein E3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.